Forbes

CBS news correspondent Natalie Morales talks about mother-in-law Kay Rhodes's diagnosis of early-onset Alzheimer's disease back in 2000 and what's different now.

Ambient AI is transforming clinical documentation. But what happens when patients can audit the record, not the source?

The growth of influencers in the longevity medicine space is rapidly expanding, but also the need for physician, regulatory and public scrutiny.

Upheaval at the U.S. Preventive Services Task Force may reshape coverage of preventive care by insurance, possibly leading to removal of previously covered items.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.

Healthcare costs are rising 18% for small-and mid-sized businesses as employers grapple with a surge in inflation and medical expenses, a Morgan Health report shows.

The 12-lead ECG hasn't changed in a century. The algorithms reading it have. Three CEOs and one educator on whether doctors should trust the model

As interest in peptide therapy continues to grow, CeliaRx is positioning itself as a trusted destination for personalized, physician-guided peptide care.

In this week’s edition of InnovationRx, we look at breakthroughs from ASCO, Harrison.ai's U.S. expansion, Clear's move into healthcare and more.

New York Knicks big man Karl-Anthony Towns, who will play a big role against the San Antonio Spurs in the NBA Finals, talked how he manages his pain and recovery.

After conquering airport security checkpoints, Clear’s billionaire CEO Caryn Seidman Becker wants to use your biometrics to unlock doctors’ appointments, baseball games and the rest of your life.

Whether American healthcare reorganizes around prevention will be a test of the quality of its leadership.

A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer patients

While the most favored nation initiatives have bold aims to lower the cost of drugs, the impact is limited, and in some instances unclear, a case of style over substance.

A physician assistant with no symptoms and a clear colonoscopy was three years from her next screening. A blood test found Stage 3 colon cancer